BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

612 related articles for article (PubMed ID: 20194714)

  • 21. PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver.
    Maier H; Isogawa M; Freeman GJ; Chisari FV
    J Immunol; 2007 Mar; 178(5):2714-20. PubMed ID: 17312113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells.
    Borkner L; Kaiser A; van de Kasteele W; Andreesen R; Mackensen A; Haanen JB; Schumacher TN; Blank C
    Cancer Immunol Immunother; 2010 Aug; 59(8):1173-83. PubMed ID: 20349059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells.
    Parekh VV; Lalani S; Kim S; Halder R; Azuma M; Yagita H; Kumar V; Wu L; Kaer LV
    J Immunol; 2009 Mar; 182(5):2816-26. PubMed ID: 19234176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
    Brown JA; Dorfman DM; Ma FR; Sullivan EL; Munoz O; Wood CR; Greenfield EA; Freeman GJ
    J Immunol; 2003 Feb; 170(3):1257-66. PubMed ID: 12538684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity.
    Prins RM; Craft N; Bruhn KW; Khan-Farooqi H; Koya RC; Stripecke R; Miller JF; Liau LM
    J Immunol; 2006 Jan; 176(1):157-64. PubMed ID: 16365406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional tumor specific CD8 + T cells in spleen express a high level of PD-1.
    Wang Z; Chen T; Lin W; Zheng W; Chen J; Huang F; Xie X
    Int Immunopharmacol; 2020 Mar; 80():106242. PubMed ID: 32014811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lymphopenic condition enhanced the antitumor immunity of PD-1-knockout T cells mediated by CRISPR/Cas9 system in malignant melanoma.
    Yang Z; Wu H; Lin Q; Wang X; Kang S
    Immunol Lett; 2022 Oct; 250():15-22. PubMed ID: 36174769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of Photodynamic Therapy and a Flagellin-Adjuvanted Cancer Vaccine Potentiated the Anti-PD-1-Mediated Melanoma Suppression.
    Hwang HS; Cherukula K; Bang YJ; Vijayan V; Moon MJ; Thiruppathi J; Puth S; Jeong YY; Park IK; Lee SE; Rhee JH
    Cells; 2020 Nov; 9(11):. PubMed ID: 33171765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 5-Aminolevulinic acid/sodium ferrous citrate enhanced the antitumor effects of programmed cell death-ligand 1 blockade by regulation of exhausted T cell metabolism in a melanoma model.
    Hu X; Que W; Hirano H; Wang Z; Nozawa N; Ishii T; Ishizuka M; Ito H; Takahashi K; Nakajima M; Tanaka T; Zhu P; Guo WZ; Li XK
    Cancer Sci; 2021 Jul; 112(7):2652-2663. PubMed ID: 33934440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice.
    Liu Y; Peng Y; Mi M; Guevara-Patino J; Munn DH; Fu N; He Y
    J Immunol; 2009 May; 182(10):5960-9. PubMed ID: 19414747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.
    Kaplan JM; Yu Q; Piraino ST; Pennington SE; Shankara S; Woodworth LA; Roberts BL
    J Immunol; 1999 Jul; 163(2):699-707. PubMed ID: 10395660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunosensitization with a Bcl-2 small molecule inhibitor.
    Begley J; Vo DD; Morris LF; Bruhn KW; Prins RM; Mok S; Koya RC; Garban HJ; Comin-Anduix B; Craft N; Ribas A
    Cancer Immunol Immunother; 2009 May; 58(5):699-708. PubMed ID: 18807035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C).
    Salem ML; Díaz-Montero CM; Al-Khami AA; El-Naggar SA; Naga O; Montero AJ; Khafagy A; Cole DJ
    J Immunol; 2009 Feb; 182(4):2030-40. PubMed ID: 19201856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells.
    Church SE; Jensen SM; Antony PA; Restifo NP; Fox BA
    Eur J Immunol; 2014 Jan; 44(1):69-79. PubMed ID: 24114780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
    Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
    Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer.
    Binder DC; Engels B; Arina A; Yu P; Slauch JM; Fu YX; Karrison T; Burnette B; Idel C; Zhao M; Hoffman RM; Munn DH; Rowley DA; Schreiber H
    Cancer Immunol Res; 2013 Aug; 1(2):123-33. PubMed ID: 24455752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(+) T cells in NOD/SCID/IL2Rg(null) mice.
    van der Waart AB; Fredrix H; van der Voort R; Schaap N; Hobo W; Dolstra H
    Cancer Immunol Immunother; 2015 May; 64(5):645-54. PubMed ID: 25724840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo.
    Paterson AM; Brown KE; Keir ME; Vanguri VK; Riella LV; Chandraker A; Sayegh MH; Blazar BR; Freeman GJ; Sharpe AH
    J Immunol; 2011 Aug; 187(3):1097-105. PubMed ID: 21697456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells.
    Iraolagoitia XL; Spallanzani RG; Torres NI; Araya RE; Ziblat A; Domaica CI; Sierra JM; Nuñez SY; Secchiari F; Gajewski TF; Zwirner NW; Fuertes MB
    J Immunol; 2016 Aug; 197(3):953-61. PubMed ID: 27342842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo.
    Lou Y; Wang G; Lizée G; Kim GJ; Finkelstein SE; Feng C; Restifo NP; Hwu P
    Cancer Res; 2004 Sep; 64(18):6783-90. PubMed ID: 15374997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.